HESKA CORP
Healthcare · In Vitro & In Vivo Diagnostic Substances · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $257.3M | $253.7M | $197.3M | $122.7M | $127.4M | $129.3M |
| Operating income | −$20.3M | −$993,000 | −$8.2M | $327,000 | $3.8M | $18.2M |
| Net income | −$19.9M | −$1.1M | −$14.4M | −$1.5M | $5.8M | $10.0M |
| Total assets | $585.8M | $604.1M | $399.8M | $244.4M | $156.5M | $135.4M |
| Total liabilities | $163.6M | $168.2M | $112.8M | $89.9M | $34.0M | $35.0M |
| Equity | $422.2M | $435.9M | $287.1M | $154.4M | $122.4M | $100.4M |
| EPS (diluted) | $-1.92 | $-0.11 | $-1.66 | $-0.20 | $0.74 | $1.30 |
| Shares out. | 10.8M | 9.5M | 7.8M | 7.7M | 7.3M | 7.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −7.9%
- Net margin
- −7.7%
- Return on equity
- −4.7%
- Return on assets
- −3.4%
- Return on capital (ROCE)
- −3.7%
- Liabilities / assets
- 27.9%
- Debt / equity
- 0.39×
- Book value / share
- $39.05
- Revenue growth (YoY)
- 1.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- 4.06safe
- Accruals / assets
- 0.3%clean
- Beneish M-Score
- -2.39normal
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Debt acceleration / triggering eventJun 13, 2023
- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJun 13, 2023
- Shareholder voteJun 7, 2023
- Other material eventJun 1, 2023
- Other material eventMay 26, 2023
- Results of operationsMay 5, 2023
- Director / officer change · Shareholder voteMay 3, 2023
- Entered a material agreement · Other material eventApr 3, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.